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ABSTRACT
Background: Observational studies suggest that high dairy intake is
associated with a lower blood pressure (BP).
Objective: We aimed to investigate the effect of a high-dairy
diet (HDD) as compared with a low-dairy diet (LDD) on BP in
overweight middle-aged adults.
Methods: Fifty-two overweight men and women were included in a
randomized crossover intervention study. Each subject consumed 2
isocaloric diets for 6 wk, an LDD (≤1 dairy portion per day) and
an HDD (6 or 5 reduced-fat dairy portions for men and women,
respectively), with a 4-wkwashout period in between the diets during
which the subjects consumed their habitual diet. BP was measured
at the start and at the end of the intervention diets. The effect of
the intervention study was evaluated by 2-sample t tests. Mixed-
model analyses were used for adjustment for the potential influence
of changes in dietary protein and mineral intake and risk factors for
hypertension including body weight and plasma cholesterol.
Results:Consumption of anHDDas comparedwith an LDD resulted
in a reduction of both systolic BP (mean ± SD: 4.6 ± 11.2 mm Hg,
P < 0.01) and diastolic BP (3.0 ± 6.7 mm Hg, P < 0.01). In further
analyses, these reductions appeared dependent on the concomitant
increase in calcium intake.
Conclusions: This intervention study shows that an HDD results in
a reduction of both systolic and diastolic BP in overweight middle-
aged men and women. If the results of our study are reproduced by
other studies, advice for high dairy intake may be added to treatment
and prevention of high BP. This trial was registered at trialregister.nl
as NTR4899. Am J Clin Nutr 2019;00:1–9.
Keywords: dairy, blood pressure, crossover study, intervention
study, randomized controlled trial, dairy diet, intervention diet
Introduction
Hypertension is an important risk factor for various cardiovas-
cular diseases, including stroke, coronary artery disease, heart
failure, and peripheral vascular disease (1). According to the
LifeLines Cohort Study, conducted in the Netherlands, 23% of
people between the age of 18 and 65 y and 69% of people above
the age of 65 y had hypertension in 2013 (2). According to the
NHANES, 34% of people in the United States above the age of
20 y had hypertension between 2011 and 2014 (3). As a result,
hypertension places an immense burden on the health care system
with estimated direct and indirect costs of $53.2 billion dollars for
the US in 2013 (3).
Blood pressure (BP) is largely lifestyle related and one of the
ways BP can be modified is by diet. Well-established dietary
modifications that lower BP are weight loss, lowering dietary salt
intake, an increase of dietary potassium intake, and moderation
of alcohol consumption (4). Also, strong and consistent evidence
demonstrates that the Dietary Approaches to Stop Hypertension
(DASH) diet, which is rich in fruits, vegetables, legumes, and
low-fat dairy products, and is low in snacks, sweets, meat, and
saturated and total fat, has a BP-lowering effect (4–6). A recently
performed review estimated the specific contribution of dairy
in the BP-lowering effect of the DASH diet to be 50% (7).
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However, because of differences in macronutrient composition
of the various diets in the original DASH trial, this estimated
contribution remains uncertain (7).
It is often suggested that dairy has an important BP-lowering
effect, and that the concomitant increase in dietary intake
of protein, calcium, potassium, and magnesium may mediate
this effect (8–11). Accordingly, epidemiological studies are
consistent in showing an inverse association between dairy intake
and BP, as well as an inverse association between dairy and stroke
(7). However, in 2010, the US Dietary Guidelines Advisory
Committee (DGAC) concluded that there is too little evidence
that supports an independent relation between the intake of dairy
and BP to allow for recommendation of high dairy intake as
part of a BP-lowering diet (12). Therefore, the DGAC made a
request for results of randomized controlled trials (RCTs) that
attempt to answer the question whether intake of dairy products
alters BP.
It should be noted that for public health advice it is important
that the study design is close to a real-life setting. Therefore, it is
important that subjects are able to freely choose how to compose
the low-dairy diet (LDD) and high-dairy diet (HDD). The aim of
this study was to investigate, in an RCT close to a Dutch real-life
setting, whether high dairy intake compared with low dairy intake
results in a change in BP and, if so, to investigate whether and to




Subjects included in the current study were healthy, over-
weight men and postmenopausal women aged between 45
and 65 y, with a BMI (in kg/m2) ≥25 to ≤30, consuming
3 main meals a day including breakfast. The subjects had a
relatively stable body weight (self-reported fluctuations in body
weight <3 kg in the past 3 mo) and had no intention to
lose weight until the end of the study. Individuals who were
involved in intensive sports activities (e.g., playing football,
tennis, running, race-cycling, swimming) more than twice a week
were excluded, as were those on any slimming or medically
prescribed diet, those who had a vegan or macrobiotic lifestyle,
or those who had a reported lactose allergy or sensitivity. Further
exclusion criteria were diabetes mellitus [using the criteria of
the American Diabetes Association (13): fasting glucose ≥7.0
mmol/L, glycated hemoglobin ≥6.5% (48 mmol/mol)], positive
HIV, hepatitis B surface antigen and/or hepatitis C infection at
screening, and clinically relevant abnormalities in blood lipids
(total cholesterol >8 mmol/L, triglycerides >6 mmol/L, LDL
cholesterol>5.7 mmol/L), hematology [Hb<8.7 mmol/L (male)
or <7.5 mmol/L (female)], or markers for liver damage (alanine
aminotransferase and aspartate aminotransferase >45 U/L) and
kidney damage (urinary albumin:creatinine ratio>30mg/mmol).
Also, individuals with gastrointestinal disorders or digestive
tract surgery in the past and individuals using lipid-lowering
drugs (from screening until the end of the study) or antibiotics
(from 1 mo before screening) were excluded. The stable use
of BP-lowering medication was allowed. Intake of nutritional
supplements was not allowed from screening until the end of the
study.
Volunteers were recruited by an advertisement in a local
newspaper in 2015–2016. Those interested received an informa-
tion letter, Informed Consent Form (ICF), and a prescreening
questionnaire. Suitable participants who returned a signed ICF
and a completed questionnaire were invited for a screening
visit to check for additional inclusion and exclusion criteria.
Eventually 52 subjects were included and randomly assigned to
a “Low-High” sequence or a “High-Low” sequence (Figure 1).
Random assignment was based on minimization (using the
softwareMinim, Stephen Evans, Patrick Royston and SimonDay,
UK) (14) to ensure minimal differences in the “High-Low” and
“Low-High” sequences based on gender (male or female), age
(45–55 or 55–65 y), and BMI (25–27 or 28–30).
The study design made it impossible to blind the subjects or
the researcher and dietitians to the diet. The sample analyses and
data processingwere blinded, where plasma samples and raw data
were labeled by sequence and not by diet.
The intervention study (NTR4899) was conducted according
to the principles of the Declaration of Helsinki (last amended
by the 64th World Medical Association General Assembly,
Fortaleza, Brazil, October, 2013) and in accordance with the
Medical Research Involving Human Subjects Act [in Dutch, the
Wet medisch-wetenschappelijk onderzoek met mensen (WMO)].
The study was approved by the Medical Ethics Committee of
the University Medical Center Groningen (UMCG), Groningen,
Netherlands (METc 2014/298).
Study design and dietary intervention
This study is a secondary outcome analysis on BP of
an RCT with crossover design conducted in the UMCG in
the Netherlands. The primary outcome of the study was
metabolic flexibility. Glycemic and insulinemic responses during
an oral-glucose-tolerance test (OGTT) and subsequent fasting,
differences in glucose kinetics during an OGTT, differences
in insulin sensitivity during an OGTT, and changes in BP
were secondary outcome variables in the research. Data on
metabolic flexibility, on glycemic and insulinemic responses
during an OGTT and subsequent fasting, on differences in
glucose kinetics during an OGTT, and on differences in insulin
sensitivity during an OGTT have been published (15). In a later
stage, samples of the underlying biobank that was established
during the study will be used for assessment of other secondary
outcomes.
The study consisted of two 6-wk intervention periods, an LDD
(≤1 portion of dairy each day) and an HDD (6 or 5 portions of
dairy each day for men and women, respectively), in random
order. The 2 intervention periods were separated with a 4-wk
washout period (Figure 2).
A portion of dairy consisted of 250 mL semiskimmed milk
or butter milk, 200 g semiskimmed yogurt, or 30 g reduced-
fat cheese (1 slice; maturity according to personal preference).
Subjects on the HDD were instructed to consume ≥1 slice (but
no more than 2 slices) of cheese and 2 portions of yogurt each
day. The remaining portions of dairy were chosen by the subjects
and had to consist of the described dairy products. No other dairy
products were allowed during either of the intervention diets,
except for the occasional use of small amounts of dairy (e.g.,
coffee creamer, cooking cream). All subjects were instructed to
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Randomly assigned (n=52)
FIGURE 1 Consolidated Standards of Reporting Trials 2010 flow diagram. HDD, high-dairy diet; LDD, low-dairy diet.
day. The food diaries had to be completed before the start, and
in week 3 and week 6, of each intervention diet. In addition, the
subjects reported daily the number and types of dairy portions
consumed. In the washout period the subjects went back to their
habitual diet.
The subjects were instructed to keep a stable body weight and
therefore the 2 intervention diets were intended to be isocaloric.
To achieve 2 isocaloric diets, the subjects were instructed by
a dietitian from the UMCG. At the start of each intervention
period, the subjects attended a consultation with the dietitian
to discuss the dietary assessment and to provide information
about restrictions and obligations of the allocated intervention
diet. Suggestions were given regarding the incorporation of a
high amount of dairy into the normal diet. When necessary, the
subjects were contacted by telephone, helping them to maintain
their body weight or to give additional advice regarding the diet.
Habitual medication had to be used in both intervention periods
and was reported in the case report form. The additional use of
paracetamol and any treatment for adverse events was allowed.
The prescribed FrieslandCampina dairy products were purchased
by the subjects at their local supermarket and the costs were
reimbursed.
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A dietitian calculated energy and nutrient intake from the food
diaries, based on the Dutch Food Composition Database 2016,
using the software program EvryDietist 6.4.2.1 (Evry BV). The
calculated dietary intakes of protein, calcium, sodium, potassium,
and magnesium were used as an indication of dietary intake.
Clinical and biochemical measurements
Clinical and biochemical tests were conducted before the start
of the intervention and at the end of the 6-wk period, at the
visit in week 6. One day before the visit in week 6, the subjects
were asked to refrain from alcohol consumption and strenuous
exercise. Also, no food and drinks were allowed after 2000 the
day before the visit in week 6, except for water. Subjects recorded
in a diary what they had for dinner the evening before the visit in
week 6 and consumed the exact same products the day before the
corresponding visit in week 6 of the second intervention diet.
Anthropometry and total body fat percentage.
Height and body weight were determined with a wall-mounted
stadiometer (Seca 222, Seca GmbH) and digital weighing scale
(Seca 877, Seca GmbH), respectively. Waist circumference
and hip circumference were determined with a measuring tape
with a standardized retraction mechanism (Seca 201, Seca
GmbH). Total body fat percentage was estimated in week 6 of
both intervention periods using a multifrequency Bioelectrical
Impedance Analyzer (QuadScan 4000, BodyStat).
BP and pulse rate.
BP and pulse rate were measured on the right arm with a BP
monitor [Omron 705IT (HEM-759P-E2), OmronHealthcare Cor-
poration]. Before the measurements, the subjects were positioned
semiupright on an examination table and were instructed not to
talk. A minimum of 2 measurements were performed and the
mean of those measurements was used in the analyses.
Blood samples.
Blood was drawn in the morning after an overnight fast
for measurements of plasma glucose, insulin, triglycerides, and
HDL, LDL, and total cholesterol. Blood samples were collected
into 2-mL BD Vacutainer NaF tubes (BD Diagnostics Benelux)
for plasma glucose, 5-mL EDTA tubes for plasma insulin, and
4.5-mL LiHep tubes for plasma triglycerides and HDL, LDL,
and total cholesterol. The blood samples were then centrifuged
at 1300 × g for 10 min at room temperature within 30 min
and after that, the samples were divided into aliquots in 500-μL
tubes and frozen at−80◦Cwithin 30 min after centrifugation. All
blood samples were measured using standard Roche Diagnostics
reagents.
Urine samples.
One day before the visit in week 6, the subjects were asked
to collect their urine for 24 h in a container and to keep it
refrigerated. The volumewas calculated by dividing the weight of
the urine by 1.015. Aliquots were frozen in 2-mL tubes at−80◦C
after centrifugation at 2000 × g for 10 min at room temperature.
The 24-h urinary excretions of urea, calcium, sodium, potassium,
and magnesium were used as a marker for dietary intake. All
measurements were performed on a Roche/Hitachi Modular
automatic analyzer (Roche Diagnostics).
Statistical analyses
Normally distributed variables are displayed as means ± SDs.
Distributions of the data were checked using histograms and nor-
mal probability (Q-Q) plots. For lognormal distributed variables,
the logarithmic values were used for statistical analyses.
Power calculation was performed based on the primary
endpoint of the original study (metabolic flexibility).
To test for a carryover effect, independent-sample t tests were
conducted to compare the sum of the outcome variables [systolic
BP (SBP), diastolic BP (DBP), and pulse rate] at the end of week
6 of both intervention periods between the group of subjects that
started with the LDD and the group of subjects that started with
the HDD.
Primary analyses were based on complete cases by means of
paired t tests. Secondary analyses were based on all subjects
who completed ≥1 intervention period and were performed by
means of mixed models. Mixed-model analyses were conducted
with SBP, DBP, and pulse rate as dependent variables. The
intervention, period, and the interaction between the intervention
and period were treated as the main fixed effects. Age, gender,
and the value of the dependent variable at baseline were added
into the mixed model as fixed effects, and so were other potential
confounders.
Paired t tests were used to test whether the dietary intake and
the 24-h urinary excretions of protein/urea, calcium, sodium,
potassium, and magnesium were different at the end of the
LDD compared with the HDD. Because dietary intakes of
protein, calcium, sodium, potassium, and magnesium are known
to affect BP (8–11), and changes in dietary intakes of these
might potentially explain changes in BP in response to the dietary
intervention, we performed separate mixed-model analyses to
which these variables were added. Protein, calcium, potassium,
and magnesium intake can be well estimated from dietary
questionnaires, but this is much less true for sodium, for
which urinary excretion serves as the gold standard (16). For
reasons of consistency, we performed separate analyses in
which we adjusted for each component derived from dietary
questionnaires and for each component derived from 24-h urinary
excretion.
Paired t tests were also used to test whether plasma cholesterol
parameters and specific subject characteristics, including body
weight, BMI, and waist circumference, were different at the
end of the LDD compared with the HDD. Because particularly
body weight, BMI, and waist circumference are known to be
related to BP (4, 17), and changes in these might potentially
explain changes in BP in response to the dietary intervention,
we performed separate mixed-model analyses in which these
variables were added. Exclusion of subjects with BP-lowering
medication did not materially change the results.
P < 0.05 was considered to be statistically significant. All
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Age, y 58.6 ± 4.8
SBP, mm Hg 133.3 ± 17.1
DBP, mm Hg 82.9 ± 9.9
Pulse rate/min 68.0 ± 8.3
Hypertension,2 n (%) 20 (38.5)
Antihypertensive treatment, n (%) 3 (5.8)
Length, cm 174.0 ± 9.5
Weight, kg 85.1 ± 10.2
BMI, kg/m2 28.0 ± 1.9
WC, cm 95.2 ± 8.6
HC, cm 107.6 ± 4.5
Glucose, mmol/L 5.6 ± 0.5
Insulin, mU/L 11.2 ± 4.2
Total cholesterol, mmol/L 5.7 ± 0.9
HDL cholesterol, mmol/L 1.5 ± 0.4
LDL cholesterol, mmol/L 3.9 ± 0.9
Triglycerides, mmol/L 1.4 ± 0.7
1Values are means ± SDs unless indicated otherwise, n = 52. Blood
lipids were measured in plasma. DBP, diastolic blood pressure; HC, hip
circumference; SBP, systolic blood pressure; WC, waist circumference.
2Hypertension is defined as SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg.
Results
Subjects
Of the 52 subjects, 44.2% were male (n = 23) and all of
them were overweight (BMI 28.0 ± 1.9) at baseline. Twenty
subjects had hypertension (SBP ≥ 140 mm Hg or DBP ≥ 90
mm Hg) at baseline and 3 subjects used BP-lowering medication
throughout the entire study. The subjects had an SBP and DBP
of 133.3 ± 17.1 and 82.9 ± 9.9 mm Hg, respectively, with
a pulse rate of 68.0 ± 8.3/min (Table 1). In total, 6 subjects
dropped out of the study after completion of 1 intervention diet
for reasons related to the primary outcomes of the original study
(1 for claustrophobia, 1 for bronchitis, 2 were sick after the
OGTT, 2 were unable to continuously draw blood) and unrelated
to the diet. One subject was excluded from analysis due to
gastrointestinal illness before the final test day. After the random
assignment, but before the start of the study, for personal practical
reasons 1 subject was switched from intervention order “High-
Low” to “Low-High.” To compensate for the dropouts, 1 extra
subject was recruited to the “High-Low” sequence, resulting in
52 subjects who completed ≥1 intervention diet. Of these, 49
subjects completed the LDD and 49 subjects completed the HDD,
resulting in 46 subjects who completed both intervention diets—
and thus there were 3 subjects who only completed the LDD
and 3 subjects who only completed the HDD (Figure 1). Primary
analyses were based on complete cases (n = 46) and secondary
analyses on all subjects that completed ≥1 intervention period
(n = 52). Subject characteristics at the end of the LDD and the
HDD are presented in Table 2. At the end of the HDD, subjects
had a slightly higher body weight (84.0 compared with 83.6 kg,
P = 0.008), and thus a slightly higher BMI (27.8 compared
with 27.7, P = 0.007), and lower plasma HDL-cholesterol
concentrations than at the end of the LDD (−0.05 mmol/L,
P = 0.002). There was no difference in waist circumference
(P= 0.195), total body fat (P= 0.212), or plasma concentrations
of total cholesterol (P = 0.622), LDL cholesterol (P = 0.777),
and triglycerides (P= 0.068) at the end of the HDD as compared
with at the end of the LDD (Table 2). The calculated total energy
intake was significantly higher during the HDD than during the
LDD (2304 compared with 2151 kcal/24 h, P= 0.021) (Table 2).
The same was true for the calculated dietary intakes of protein,
calcium, potassium, and magnesium. Also, the 24-h urinary
excretions of urea, calcium, and potassium were significantly
higher at the end of the HDD than at the end of the LDD (Table
2). There was no difference in dietary intake and 24-h urinary
excretion of sodium at the end of the HDD and at the end of the
LDD.
Intervention effect on SBP, DBP, and pulse rate
SBP and DBP were lower after the HDD than after the LDD
(127.5 comparedwith 132.1mmHg,P< 0.01 and 78.8 compared
with 81.8 mm Hg, P < 0.01, respectively) (Table 2). In further
analyses, we investigated whether the effect of the HDD as
compared with the LDD was independent of change in other
variables, data on which are listed in Supplemental Table 1.
The effect of the HDD on measured SBP and DBP remained
significant when adjusted for body weight and other potential
confounders (Table 3). Also, adjustment for the calculated
intakes of energy, protein, sodium, potassium, and magnesium
did not materially change the effect of the HDD as compared
with the LDD on SBP and DBP (Table 4). The same was
true for adjustment for 24-h urinary excretions of urea, sodium,
potassium, and magnesium (Table 5). However, the effect
of the HDD as compared with the LDD on SBP and DBP
was nonsignificant after adjustment for the dietary intake of
calcium and 24-h urinary excretion of calcium (Tables 4 and 5).
The pulse rate was not different after the HDD as compared
with the LDD (59.9 compared with 60.5/min, P = 0.36)
(Table 2).
Discussion
The aim of this study was to investigate the effect of an
HDD as compared with an LDD on BP in overweight middle-
aged adults. As mentioned before, BP is an important risk factor
for various cardiovascular diseases (1) and, therefore, it is very
important to lower BP. Previously performed prospective studies
concluded that hypertension was associated with a substantial
amount of avoidable deaths aswell as hospitalization for coronary
heart disease and stroke and, on top of that, the population
attributable risk of hypertension on mortality was 2–3 times
greater than that of diabetes (18). The population attributable
risk of hypertension on incident heart failure was greater than
those of physical inactivity, smoking, and impaired glucose
control (19). These results show the importance of BP-lowering
interventions.
In the primary analyses of cases with complete data, we found
a significant effect of the HDD as compared with the LDD on
both SBP and DBP. In secondary analyses, in which all subjects
who completed ≥1 intervention diet were included, these results
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TABLE 2 Effect of HDD versus LDD on blood pressure, body composition, blood lipids, dietary intakes, and 24-h urinary excretions1
Intervention Effect HDD as compared to LDD2
Variable LDD (n = 46) HDD (n = 46)  (n = 46) 95% CI P
Blood pressure
SBP, mm Hg 132.1 ± 15.7 127.5 ± 15.3 − 4.6 ± 11.2 − 8.0, −1.2 0.009
DBP, mm Hg 81.8 ± 9.2 78.8 ± 10.4 − 3.0 ± 6.7 − 5.0, −1.0 0.005
Pulse rate, per min 60.5 ± 7.4 59.9 ± 8.2 − 0.7 ± 5.0 − 2.2, 0.8 0.359
Body composition
Weight, kg 83.6 ± 9.8 84.0 ± 9.8 0.4 ± 1.0 0.1, 0.7 0.008
BMI, kg/m2 27.7 ± 1.9 27.8 ± 1.9 0.1 ± 0.3 0.04, 0.2 0.007
WC, cm 94.8 ± 8.7 95.2 ± 8.7 0.5 ± 2.5 − 0.3, 1.2 0.195
HC, cm 106.2 ± 4.9 106.2 ± 5.3 0.09 ± 2.3 − 0.6, 0.8 0.800
Total body fat, % 34.3 ± 8.1 34.7 ± 8.1 0.4 ± 2.1 − 0.2, 1.0 0.212
Blood lipids3
Total cholesterol, mmol/L 5.3 ± 0.9 5.2 ± 0.8 − 0.03 ± 0.4 − 0.2, 0.09 0.622
HDL-cholesterol, mmol/L 1.4 ± 0.4 1.4 ± 0.3 − 0.05 ± 0.1 − 0.09, −0.02 0.002
LDL-cholesterol, mmol/L 3.6 ± 0.8 3.5 ± 0.8 − 0.02 ± 0.4 − 0.1, 0.09 0.777
Triglycerides, mmol/L 1.2 ± 0.5 1.2 ± 0.6 0.1 ± 0.4 − 0.008, 0.2 0.068
Dietary intakes4
Energy, kcal/d 2151.1 ± 461.8 2304.4 ± 589.7 153.3 ± 424.7 24.2, 282.4 0.021
Protein, g/d 78.4 ± 18.0 109.3 ± 25.6 30.9 ± 19.3 25.1, 36.8 <0.001
Calcium, mg/d 719.0 ± 157.4 1956.8 ± 283.0 1237.8 ± 303.0 1145.7, 1329.9 <0.001
Sodium, mg/d 2621.4 ± 691.6 2742.5 ± 803.3 121.2 ± 873.5 − 144.4, 386.7 0.363
Potassium, mg/d 3379.9 ± 673.9 4100.2 ± 847.4 720.4 ± 809.6 474.2, 966.5 <0.001
Magnesium, mg/d 363.0 ± 99.2 409.4 ± 93.0 46.5 ± 114.0 11.8, 81.1 0.010
24-h urinary excretions, mmol/24 h
Urea 377.1 ± 126.8 482.0 ± 121.9 104.9 ± 123.8 68.1, 141.6 <0.001
Calcium 4.1 ± 1.8 5.0 ± 2.4 0.8 ± 1.7 0.3, 1.4 0.002
Sodium 148.0 ± 63.1 145.1 ± 67.4 − 2.9 ± 56.9 − 19.8, 14.0 0.729
Potassium 85.8 ± 25.7 98.7 ± 27.6 12.9 ± 29.3 4.2, 21.6 0.005
Magnesium 4.7 ± 2.0 4.5 ± 1.4 − 0.2 ± 2.2 − 0.8, 0.5 0.563
1Values are presented as mean ± SD. Analyses were performed based on complete cases. P values were obtained from paired t tests. DBP, diastolic
blood pressure; HC, hip circumference; HDD, high dairy diet; LDD, low dairy diet; SBP, systolic blood pressure; WC, waist circumference.
2 was calculated as LDD minus HDD.
3Blood lipids were measured in plasma.
4Dietary intakes were calculated from food diaries.
in which the use of mixed models allowed for adjustment for
the potential influence of changes in calculated dietary intakes
of protein, calcium, sodium, potassium, and magnesium on the
effect on BP, we found no indication of mediation of the effect of
the HDD onBP by higher dietary intake of either protein, sodium,
potassium, or magnesium. These secondary analyses strongly
support the notion that the BP-lowering effect of high dairy
intake is independent of concomitant changes in other dietary
components that have been implicated in BP regulation, because
high dietary intakes of protein, potassium, and magnesium have
been shown to have BP-lowering effects, whereas high dietary
intake of sodium has been shown to have BP-raising effects
(10, 20–23). The effect of the HDD on BP appeared, however,
entirely dependent on the concomitant change in dietary intake of
TABLE 3 Results of mixed-model analyses with adjustment for changes in body composition and plasma HDL cholesterol1
Systolic blood pressure (n = 52) Diastolic blood pressure (n = 52) Pulse rate (n = 52)
Model  (95% CI)2 P  (95% CI)2 P  (95% CI)2 P
1 − 7.1 (−13.0, −1.2) 0.019 − 5.9 (−10.2, −1.5) 0.008 − 1.7 (−5.0, 1.6) 0.312
2 − 7.5 (−13.2, −1.7) 0.011 − 6.0 (−10.2, −1.7) 0.007 − 1.8 (−5.1, 1.4) 0.266
3 − 6.7 (−12.6, −0.8) 0.028 − 5.4 (−9.8, −1.1) 0.015 − 1.5 (−4.8, 1.8) 0.375
4 − 7.1 (−13.0, −1.3) 0.018 − 5.7 (−10.0, −1.5) 0.009 − 1.7 (−5.0, 1.6) 0.309
5 − 6.9 (−12.8, −0.9) 0.024 − 5.6 (−10.0, −1.2) 0.013 − 1.5 (−4.8, 1.7) 0.353
6 − 7.0 (−12.9, −1.1) 0.021 − 5.8 (−10.1, −1.4) 0.010 − 1.7 (−5.0, 1.7) 0.325
1Analyses were performed with all subjects who completed ≥1 intervention diet. Model 1: adjusted for period and intervention × period, gender, age,
energy intake (kcal), and baseline value of the variable. Model 2: model 1 + weight (kg). Model 3: model 1 + BMI (kg/m2). Model 4: model 1 + waist
circumference (cm). Model 5: model 1 + total body fat (%). Model 6: model 1 + plasma HDL cholesterol (mmol/L).
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TABLE 4 Results of mixed-model analyses with adjustment for changes in dietary intakes1
Systolic blood pressure (n = 52) Diastolic blood pressure (n = 52) Pulse rate (n = 52)
Model  (95% CI)2 P  (95% CI)2 P  (95% CI)2 P
1 − 6.5 (−12.4, −0.7) 0.029 − 5.5 (−9.8, −1.2) 0.012 − 1.8 (−5.1, 1.4) 0.271
2 − 7.1 (−13.0, −1.2) 0.019 − 5.9 (−10.2, −1.5) 0.008 − 1.7 (−5.0, 1.6) 0.312
3 − 8.5 (−15.4, −1.6) 0.017 − 5.7 (−10.9, −0.6) 0.030 − 1.9 (−5.7, 1.9) 0.322
4 2.3 (−12.2, 16.7) 0.755 − 0.8 (−11.4, 9.8) 0.883 2.1 (−6.3, 10.4) 0.623
5 − 6.1 (−12.6, −0.8) 0.026 − 5.5 (−9.8, −1.2) 0.013 − 1.7 (−5.1, 1.6) 0.294
6 − 6.9 (−13.3, −0.5) 0.034 − 4.8 (−9.4, −0.1) 0.046 − 0.7 (−4.3, 2.8) 0.682
7 − 7.5 (−13.5, −1.5) 0.015 − 5.9 (−10.3, −1.5) 0.010 − 1.3 (−4.7, 2.0) 0.431
1Analyses were performed with all subjects who completed ≥1 intervention diet. Model 1: adjusted for period and intervention × period, gender, age,
and baseline value of the variable. Model 2: model 1 + energy intake (kcal/d). Model 3: model 1 + protein intake (g/d). Model 4: model 1 + calcium intake
(mg/d). Model 5: model 1 + sodium intake (mg/d). Model 6: model 1 + potassium intake (mg/d). Model 7: model 1 + magnesium intake (mg/d).
2 was calculated as low-dairy diet minus high-dairy diet.
calcium. This was supported by the secondary analyses in which
we adjusted for the 24-h urinary excretions of urea, calcium,
sodium, potassium, and magnesium.
Interestingly, a recently performed review and meta-analysis
of RCTs, investigating the effects of calcium plus vitamin D
supplementation on BP, found no effect on BP (24). It can be
hypothesized that calcium in combination with other minerals
in dairy has a stronger effect on BP than calcium alone. This
hypothesis is supported by Houston and Harper (25), who
suggested that calcium in combination with other ions, including
sodium, potassium, and magnesium, provides an ionic balance
that results in the reduction of BP. It is also known that microbial
SCFAs, which are byproducts of microbial metabolism and are
formed after the consumption of yogurt, lower BP through their
effect on the renin–angiotensin system (26). However, SCFAs
are also produced by the fermentation of dietary fibers, which
were more prominently present in the diet while subjects were on
the LDD than while they were on the HDD. Alternatively, these
results may be explained by the fact that dietary intake of calcium
and 24-h urinary excretion of calcium are merely statistical—
and not necessarily causal—intermediates between dairy intake
and BP, which makes it hard to draw firm conclusions on actual
causality.
This study is, to our knowledge, the first to present a reduction
of both SBP and DBP after an HDD, where many other studies
only found a reduction of SBP (27–29) or no reduction of BP
at all (30–34). Dairy contains several components including the
amino acid cysteine, that through several mechanisms, including
increased synthesis of the vasodilator gas hydrogen sulfide,
results in vasodilatation and may thereby have an effect on
BP (35, 36). Because the production, release, and availability
of nitrogen monoxide are important for vasodilatation, and
because dairy is a source of cysteine and indirectly a source
of nitrogen monoxide, it is possible that the established BP-
lowering effect of dairy is achieved by increased dietary intake of
cysteine.
Although we expected the 6-wk intervention periods to be long
enough to induce an effect of dairy on BP (28), Wennersberg et
al. (32) found no effect of dairy on BP, attributing that to a “short
intervention period” of 6 mo. A possible explanation might be
that dairy has a BP-lowering effect in the short term, whereas
the body eventually regulates the BP back to its former range
over a longer term. Contradicting, however, are the results of the
meta-analysis of observational studies performed by Lee et al.
(37), that concluded that an increased intake of 200 g dairy/d was
associated with lower BP.
Strengths of the study include the crossover design, the few
dropouts, and the consultations by a dietitian to increase the
compliance of the subjects to the diets throughout the entire
study. The real-life setting of the study design means that the
TABLE 5 Results of mixed-model analyses with adjustment for changes in 24-h urine excretion1
Systolic blood pressure (n = 52) Diastolic blood pressure (n = 52) Pulse rate (n = 52)
Model  (95% CI)2 P  (95% CI)2 P  (95% CI)2 P
1 − 6.5 (−12.4, −0.7) 0.029 − 5.5 (−9.8, −1.2) 0.012 − 1.8 (−5.1, 1.4) 0.271
2 − 7.0 (−12.9, −1.1) 0.020 − 5.8 (−10.1, −1.6) 0.008 − 1.7 (−5.1, 1.8) 0.340
3 − 4.7 (−10.7, 1.3) 0.121 − 3.5 (−7.8, 0.8) 0.111 − 0.7 (−3.9, 2.6) 0.691
4 − 6.6 (−12.5, −0.8) 0.027 − 5.5 (−9.8, −1.2) 0.014 − 1.8 (−5.0, 1.5) 0.279
5 − 6.6 (−12.7, −0.6) 0.032 − 4.9 (−9.3, −0.5) 0.030 − 0.7 (−3.9, 2.5) 0.668
6 − 6.4 (−12.2, −0.6) 0.032 − 5.3 (−9.5, −1.0) 0.015 − 1.6 (−4.7, 1.6) 0.319
1Analyses were performed with all subjects who completed ≥1 intervention diet. Model 1: adjusted for period and intervention × period, gender, age,
and baseline value of the variable. Model 2: model 1 + 24-h urinary excretion of urea (mmol/24 h). Model 3: model 1 + 24-h urinary excretion of calcium
(mmol/24 h). Model 4: model 1 + 24-h urinary excretion of sodium (mmol/24 h). Model 5: model 1 + 24-h urinary excretion of potassium (mmol/24 h).
Model 6: model 1 + 24-h urinary excretion of magnesium (mmol/24 h).
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results may be extrapolated to Dutch residents. Besides that, the
6-wk intervention periods were expected to be sufficiently long
to induce an effect of the intervention diets on BP (28), but
short enough to ensure compliance from the subjects. However,
there are some limitations of the current study. Despite a 4-
wk washout period, a significant interaction indicated a possible
carryover effect for BP. Besides that, subjects gained weight
during the HDD which is most likely due to higher energy
intake, despite efforts to make the diets isocaloric. At the end
of each intervention period, we performed a minimum of 2 BP
measurements and used the mean of those measurements for
analyses. It would have been preferable to have taken 3 BP
measurements each day for several sequential days at the end
of each intervention period. These limitations may have led to
underestimation of the effect of dairy on BP.
In conclusion, the current literature provides evidence that
an HDD reduces SBP. However, our crossover study found a
reduction of both SBP and DBP after a high dairy intake, which
may be explained by the fact that many studies were performed
with other types of dairy products and many already performed
intervention studies seem to be biased in several aspects. For
example, it was unclear how data were obtained, dropout reasons
were not reported, and many crossover studies did not test for
a possible carryover effect and, besides that, many intervention
diets were designed to achieve weight loss, which may have
explained the BP-lowering effect of dairy in some studies. We
also found a statistically significant reduction of plasma HDL
cholesterol after the HDD, whereas changes in other blood lipids
were nonsignificant.
The BP-lowering effect of dairy in our study was explained
by the concomitant increase in dietary intake of calcium. The
BP-lowering effect was independent of the higher dietary intakes
of protein, potassium, and magnesium, and also independent of
lower dietary intake of sodium.
The present study introduces dairy as a possible nourishment
that may contribute to the reduction of BP. Dairy may therefore
contribute to the prevention of cardiovascular diseases. However,
this study is the first to suggest that dairy has a DBP-lowering
effect besides the already suggested SBP-lowering effect. There
is still need for further research to investigate the DBP-lowering
effect of dairy. Also, potential effects on plasma HDL cholesterol
require further attention. Only then can dairy be safely embedded
in the prevention and treatment of both systolic and diastolic
hypertension.
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